Search

Home > Industry Focus > Healthcare: Is This Highly-Anticipated Gene Therapy In Trouble?
Podcast: Industry Focus
Episode:

Healthcare: Is This Highly-Anticipated Gene Therapy In Trouble?
Category: Business
Duration: 00:22:27
Publish Date: 2019-04-24 14:30:00
Description:

An infant participating in Novartis' Zolgensma trial has died, raising questions ahead of an expected FDA decision next month for this one-and-done treatment for spinal muscular atrophy. Here's what you should know. Also, why investors should ignore Intuitive Surgical's first quarter earnings miss and buy shares on sale.

Check out more of our content here:
Total Play: 0

Users also like

0 Episodes
MarketFooler .. 100+     6
700+ Episodes
Rule Breaker .. 200+     6
2K+ Episodes
Motley Fool .. 300+     10+

Some more Podcasts by The Motley Fool

300+ Episodes
Motley Fool ..    
700+ Episodes
Rule Breaker .. 200+     6
400+ Episodes
Motley Fool .. 100+     5
2K+ Episodes
Motley Fool .. 300+     10+
2K+ Episodes
Motley Fool ..